Phase III Data on Novartis' RLX030 - Analyst Blog


Switzerland-based pharmaceutical company, Novartis AG ( NVS ) recently announced phase III data on its pipeline candidate, RLX030 (serelaxin), from the six month, RELAX-AHF study.

The study showed that treatment with RLX030 reduced the rate of mortality in patients suffering from acute heart failure (AHF), which has a higher death rate compared to other cardiovascular diseases.

The phase III RELAX-AHF study had two primary objectives which used different scales for measuring the reduction in dyspnea. The study managed to achieve one of the primary objectives. The study also revealed that RLX030 was well tolerated in patients.

The randomized, double-blind study, RELAX-AHF was conducted in 1,161 patients in 11 countries. The study evaluated the safety and efficacy of the candidate, RLX030, in the AHF indication versus placebo.

RLX030 along with loop diuretics and other medicines was administered to patients for up to 48 hours following hospitalization.

Novartis intends to discuss the results from the study with regulatory authorities around the globe. Data from the study will also be presented at the American Heart Association congress in November 2012.

Already approved heart failure treatments include AstraZeneca 's ( AZN ) Toprol XL and Merck & Co. 's ( MRK ) Prinvil.

We remind investors that in August 2012, Novartis had reported positive phase II data on its pipeline candidate, LCZ696, from the PARAMOUNT study for the treatment of chronic heart failure.

The study showed significant reduction in a key indicator of morbidity and mortality in patients suffering from chronic heart failure with preserved ejection fraction (HF-PEF).

Our Recommendation

Currently, we have a Neutral recommendation on Novartis. Novartis carries a Zacks #3 Rank (Hold rating) in the short run.

ASTRAZENECA PLC (AZN): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: AZN , MRK , NVS

More from

Related Videos



Most Active by Volume

  • $10.26 ▼ 6.81%
  • $15.58 ▼ 1.08%
  • $7.13 ▲ 51.06%
  • $112.12 ▲ 2.39%
  • $13.49 ▲ 0.22%
  • $27.86 ▲ 2.50%
  • $5.67 ▼ 0.18%
  • $28.07 ▲ 0.14%
As of 10/9/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by